SCHEMBL6478147

SCHEMBL6478147

O=C(Nc1ccc(Cl)c(-c2ccc(Cl)cc2)c1)Nc1ccccc1CCO

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 5/20 0.65
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
ALDH1A1 P00352 2/20 0.55
CNR1 P21554 5/20 0.48
IDH1 O75874 2/20 0.47
NPC1 O15118 4/20 0.47
MAPT P10636 3/20 0.47
RAB9A P51151 3/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
LMNA P02545 2/20 0.47
EPHX1 P07099 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
CHRM1 P11229 1/20 0.47
SLC6A2 P23975 1/20 0.47
PDE4A P27815 1/20 0.47
EPHX2 P34913 1/20 0.47
ADRA1A P35348 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480232 0.90 TRPV1 (0.62) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6489077 0.85 TRPV1 (0.74) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6488133 0.85 CNR1 (0.64) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6478899 0.81 TRPV1 (0.59) TRPV1MEN1KMT2ASMN1; SMN2CNR1
SCHEMBL6479587 0.81 TRPV1 (0.56) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL23831812 0.80 TRPV1 (0.63) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30792273 0.80 TRPV1 (0.63) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL23831565 0.80 TRPV1 (0.62) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6489149 0.79 TRPV1 (0.59) TRPV1MEN1KMT2AALDH1A1CNR1
SCHEMBL6490705 0.79 TRPV1 (0.58) TRPV1MEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154230-A1 Urea derivatives BAYER HEALTHCARE AG (DE) 2005-07-14 US claimed
US-20050154230-A1 Urea derivatives BAYER HEALTHCARE AG (DE) 2005-07-14 US disclosed
EP-1461311-A2 UREA DERIVATIVES AS VR1-ANTAGONISTS Bayer HealthCare AG (DE) 2004-09-29 EP disclosed
WO-2003055848-A2 UREA DERIVATIVES AS VR1- ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154230-A1 Urea derivatives SLC14A1, UBA1, VAT1 TRPV1 214/4885MEN1 4397/4885KMT2A 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.